Market Overview:
The global valley fever treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of valley fever, rising awareness about valley fever and its diagnosis and treatment, and the launch of new drugs for the treatment of valley fever. However, factors such as high cost of therapy and lack of reimbursement are restraining the growth of this market. The global Valley Fever Treatment Market is segmented on the basisof type into fluconazole, itraconazole, voriconazole, posaconazole, and others. Onthe basisof application, it is segmented into people (adultsand children), cattle (ruminantsand dairy), sheepand goats(sheep/lambs/kids), camelids(llamas/alpacas/camels), poultry(chickens/turkeys), swine(pigs), horses(horses& donkeys)others).
Product Definition:
Valley Fever Treatment is the use of any medication or other therapy to treat Valley Fever. It is important because Valley Fever can cause serious health problems if not treated.
Fluconazole:
Fluconazole is an antifungal medication primarily used to treat fungal infections. It works by killing the fungal cells that are responsible for infection. Fluconazole may be given with amphotericin B (a drug of choice in severe fungal infections) or it can be used as monotherapy.
Itraconazole:
Itaconazole is an anti-fungal medication used to treat fungal infections. It is also used in the treatment of systemic fungal infection, blastomycosis, and by extension some mycotic infections. Itraconazole has a wide spectrum of activity against several fungi including Candida albicans, Aspergillus niger and others. The drug works by inhibiting ergosterol synthesis which results in the death of fungal cells.
Application Insights:
The market is segmented by application into people, cattle, sheep and goats, camels and other animals, and others. The people application segment dominated the overall industry in terms of revenue in 2017. Valley fever is a disease that mainly affects humans living in high altitude regions with mild winters. It has been observed that valley fever predominantly affects human males above 40 years of age who have spent time outdoors for extended periods of time or work at jobs where they spend long hours outside during summer months. This factor is anticipated to drive demand over the forecast period as valley fever primarily occurs due to fungal infection within lungs which spreads from one person to another through respiratory secretions or sweat when directly contacted by skin surfaces such as eyes, mouth or nose without proper ventilation there will be an increase risk of fungal infection among susceptible individuals leading to increased demand for anti-fungal drugs across the globe.
Regional Analysis:
North America dominated the global valley fever treatment market in 2017. The presence of key players, favorable reimbursement policies and increasing prevalence of the disease are some factors responsible for its large share. In addition, growing awareness about drug therapies is expected to drive regional growth over the forecast period.
Asia Pacific is expected to witness lucrative growth over the next eight years owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India. Moreover, a high proportion of people suffering from different types of fungal infections will also boost demand for anti-fungal drugs in this region. Favorable government initiatives regarding reimbursement policies are also anticipated to contribute toward regional market development during the forecast period (2018 - 2030).
Growth Factors:
- Increasing incidence of Valley Fever: The incidence of Valley Fever is increasing globally due to various factors such as changing climate, growing population and increasing travel. This is expected to drive the growth of the Valley Fever Treatment market during the forecast period.
- Rising awareness about Valley Fever: There is a rising awareness about Valley Fever among people due to its increasing prevalence. This is expected to lead to an increase in demand for its treatment, thereby driving the growth of the market during the forecast period.
- Growing number of research and development activities for new treatments: There is a growing number of research and development activities for new treatments for Valley Fever by pharmaceutical companies globally. This is expected to fuel the growth of the market duringthe forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Valley Fever Treatment Market Research Report
By Type
Fluconazole, Itraconazole, Voriconazole, Posaconazole, Others
By Application
People, Cattle, Sheep and Goats, Camel, Others
By Companies
Novartis, Pfizer, GlaxoSmithKline, Johnson & Johnson, Galderma, Bristol Meyer Squibb, Bausch Health Companies
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
221
Number of Tables & Figures
155
Customization Available
Yes, the report can be customized as per your need.
Global Valley Fever Treatment Market Report Segments:
The global Valley Fever Treatment market is segmented on the basis of:
Types
Fluconazole, Itraconazole, Voriconazole, Posaconazole, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
People, Cattle, Sheep and Goats, Camel, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- GlaxoSmithKline
- Johnson & Johnson
- Galderma
- Bristol Meyer Squibb
- Bausch Health Companies
Highlights of The Valley Fever Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Fluconazole
- Itraconazole
- Voriconazole
- Posaconazole
- Others
- By Application:
- People
- Cattle
- Sheep and Goats
- Camel
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Valley Fever Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no specific treatment for valley fever, but it can be treated with antibiotics if it is caused by a bacterial infection. If the cause of valley fever is unknown, then treatment may include rest and fluids to relieve symptoms.
Some of the key players operating in the valley fever treatment market are Novartis, Pfizer, GlaxoSmithKline, Johnson & Johnson, Galderma, Bristol Meyer Squibb, Bausch Health Companies.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Valley Fever Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Valley Fever Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Valley Fever Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Valley Fever Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Valley Fever Treatment Market Size & Forecast, 2018-2028
4.5.1 Valley Fever Treatment Market Size and Y-o-Y Growth
4.5.2 Valley Fever Treatment Market Absolute $ Opportunity
Chapter 5 Global Valley Fever Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Valley Fever Treatment Market Size Forecast by Type
5.2.1 Fluconazole
5.2.2 Itraconazole
5.2.3 Voriconazole
5.2.4 Posaconazole
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Valley Fever Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Valley Fever Treatment Market Size Forecast by Applications
6.2.1 People
6.2.2 Cattle
6.2.3 Sheep and Goats
6.2.4 Camel
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Valley Fever Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Valley Fever Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Valley Fever Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Valley Fever Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Valley Fever Treatment Market Size Forecast by Type
9.6.1 Fluconazole
9.6.2 Itraconazole
9.6.3 Voriconazole
9.6.4 Posaconazole
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Valley Fever Treatment Market Size Forecast by Applications
9.10.1 People
9.10.2 Cattle
9.10.3 Sheep and Goats
9.10.4 Camel
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Valley Fever Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Valley Fever Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Valley Fever Treatment Market Size Forecast by Type
10.6.1 Fluconazole
10.6.2 Itraconazole
10.6.3 Voriconazole
10.6.4 Posaconazole
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Valley Fever Treatment Market Size Forecast by Applications
10.10.1 People
10.10.2 Cattle
10.10.3 Sheep and Goats
10.10.4 Camel
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Valley Fever Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Valley Fever Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Valley Fever Treatment Market Size Forecast by Type
11.6.1 Fluconazole
11.6.2 Itraconazole
11.6.3 Voriconazole
11.6.4 Posaconazole
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Valley Fever Treatment Market Size Forecast by Applications
11.10.1 People
11.10.2 Cattle
11.10.3 Sheep and Goats
11.10.4 Camel
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Valley Fever Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Valley Fever Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Valley Fever Treatment Market Size Forecast by Type
12.6.1 Fluconazole
12.6.2 Itraconazole
12.6.3 Voriconazole
12.6.4 Posaconazole
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Valley Fever Treatment Market Size Forecast by Applications
12.10.1 People
12.10.2 Cattle
12.10.3 Sheep and Goats
12.10.4 Camel
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Valley Fever Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Valley Fever Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Valley Fever Treatment Market Size Forecast by Type
13.6.1 Fluconazole
13.6.2 Itraconazole
13.6.3 Voriconazole
13.6.4 Posaconazole
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Valley Fever Treatment Market Size Forecast by Applications
13.10.1 People
13.10.2 Cattle
13.10.3 Sheep and Goats
13.10.4 Camel
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Valley Fever Treatment Market: Competitive Dashboard
14.2 Global Valley Fever Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 GlaxoSmithKline
14.3.4 Johnson & Johnson
14.3.5 Galderma
14.3.6 Bristol Meyer Squibb
14.3.7 Bausch Health Companies
